参菝抗瘤液联合化疗治疗晚期胃癌的临床观察.pdfVIP

· 362 · WORLD CHINESEMEDICINE February2017，Vo1．12，No．2 参菝抗瘤液联合化疗治疗晚期 胃癌的临床观察 潘迎英 许 纯 (张家港市中医医院，张家港 ，215600) 摘要 目的：评价参菝抗瘤液联合化疗治疗晚期胃癌的临床疗效。方法：将40例晚期 胃癌患者随机分为治疗组 (参菝抗 瘤液 +化疗组)和对照组(化疗组)。对照组给予FOLFOX4方案化疗，治疗组同时加用参菝抗瘤液 30mL／d口服，连用 1 周，2周为一周期。结果：1)治疗组肿瘤近期客观疗效有效率高于对照组，但无统计学意义(P0．05)；2)经治疗后，治疗 组患者KPS评分升高率优于对照组，2组比较有统计学意义(P0．01)；3)治疗组体重增加及稳定者比例均高于对照组，2 组比较差异有统计学意义(尸0．05)；4)骨髓抑制比较，治疗组显著低于对照组(P0．01)；5)消化道反应比较，治疗组明 显低于对照组，化疗不良反应小(P0．05)。结论：参菝抗瘤液联合化疗治疗晚期 胃癌有改善生活质量 ，减轻化疗不良反 应的作用。 关键词 胃癌／药物治疗；抗肿瘤药(中药)／3菝抗瘤液；化学疗法 ClinicalObservationonShenbaKangliuLiquid Combined with ChemotherapyTreatingAdvancedGastricCancer PanYingying，XuChun (ZhangjiagangHospitalofTraditionalChineseMedicine，Zhangjiagang215600，China) Abstract Objective：ToevaluatetheeffectoftreatingadvancedgastriccancerwithShenbaKangliuLiquidcombinedwithchemo— therapy．Methods：Fortycasesofadvancedgastriccancerwererandomlydividedintothetreatmentgroup(ShenbaKangliuLiquid +chemotherapy)andthecontrolgroup(chemotherapy)．PatientsinthecontrolgroupwereonlyreceivedFOLFOX4，whileShen— baKangliuLiquid(30ml／d，dl一14)wasaddedforthefirstweekofrpatientsinthetreatmentgroupcombinedwithchemotherapy aswellandShenbaKangliuLiquidwasstoppedinthesecondweek．Twoweeksweresetasonecourse．Results：1)Theeffective rateofrecenttumorobjectiveefficacyinthetreatmentgroupwassuperiortothatofthecontrolgroup，showingnostatisticalsignifi— cance(P0．05)．2)KPSscoresweresignifcantlybetterinthetreatmentgroupthanthoseinthecontrolgroup．Therewassta— tisticallysignificantdifference(P0．01)．3)Changesinweightgainandpatientsstabilityofthetreatmentgroupwerebetter thanthoseinthecontrolgroup，showingstatisticalsignificance(P0．05)．4)Thebonemarrowsuppressionofthetreatment groupwasalsolowerthanthatofthecontrolgroup(P0．O1)．5)Thegastro